Last reviewed · How we verify
TWB-103
At a glance
| Generic name | TWB-103 |
|---|---|
| Also known as | Mixture of TWB-102 cell and TWB-103 hydrogel, TWB-103+Tegaderm |
| Sponsor | Transwell Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds (PHASE1, PHASE2)
- TWB-103 for Treating Lower Limb Ulcers on Patients With DM (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TWB-103 CI brief — competitive landscape report
- TWB-103 updates RSS · CI watch RSS
- Transwell Biotech Co., Ltd. portfolio CI